Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells

References

• Lindner S, Kronke J. The molecular mechanism of thalidomide analogs in hematologic malignancies. J Mol Med (Berl). 2016;94:1327–1334. doi:10.1007/s00109-016-1450-z.
   PubMed Web of Science ®Google Scholar
• Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, et al. Activity of thalidomide in AIDS-related kaposi’s sarcoma. J Clin Oncol. 2000;18:2593–2602. doi:10.1200/JCO.2000.18.13.2593.
   PubMed Web of Science ®Google Scholar
• Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, et al. Pomalidomide for symptomatic kaposi’s sarcoma in people with and without HIV infection: a phase I/II study. J Clin Oncol. 2016;34:4125–4131. doi:10.1200/JCO.2016.69.3812.
   PubMed Web of Science ®Google Scholar
• Pourcher V, Desnoyer A, Assoumou L, Lebbe C, Curjol A, Marcelin AG, Cardon F, Gibowski S, Salmon D, Chennebault J-M, et al. Phase II trial of lenalidomide in HIV-infected patients with previously treated kaposi’s sarcoma: results of the ANRS 154 lenakap trial. AIDS Res Hum Retroviruses. 2017;33:1–10. doi:10.1089/AID.2016.0069.
   PubMed Web of Science ®Google Scholar
• Shimabukuro K, Moore PC, Bui J, D’ittmer D, Ambinder R, Martinez-Maza O, et al. Lenalidomide is safe and effective in aids-associated kaposi sarcoma. 16th International Conference on Malignancies in HIV/AIDS; 2017; Bethesda, MD: National Cancer Institute.
   Google Scholar
• Liu LR, Qian SX. [Action mechanism of lenalidomide in hematological malignancies - review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20:1039–1041.
   PubMedGoogle Scholar
• Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma. 2011;52:560–566. doi:10.3109/10428194.2011.552139.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335. doi:10.1038/leu.2012.119.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang X-B, Bjorklund CC, Fonseca R, Bergsagel PL, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779. doi:10.1182/blood-2011-05-356063.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, et al. Rate of CRL4(CRBN) substrate ikaros and aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354. doi:10.1038/bcj.2015.66.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164:811–821. doi:10.1111/bjh.12708.
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58:1033–1045. doi:10.1007/s00262-008-0620-4.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–4085.
   PubMed Web of Science ®Google Scholar
• Davis DA, Mishra S, Anagho HA, Aisabor AI, Shrestha P, Wang V, Takamatsu Y, Maeda K, Mitsuya H, Zeldis JB, et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget. 2017;8:50342–50358. doi:10.18632/oncotarget.17960.
   PubMedGoogle Scholar
• Abraham C, Miller J. Molecular mechanisms of IL-2 gene regulation following costimulation through LFA-1. J Immunol. 2001;167:5193–5201.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW, Ohashi PS. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity. 1997;7:549–557.
   PubMed Web of Science ®Google Scholar
• Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol. 1990;144:4579–4586.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–258. doi:10.1146/annurev.immunol.14.1.233.
   PubMed Web of Science ®Google Scholar
• Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol. 1992;149:1115–1123.
   PubMed Web of Science ®Google Scholar
• Wilson JL, Charo J, Martin-Fontecha A, Dellabona P, Casorati G, Chambers BJ, Kiessling R, Bejarano MT, Ljunggren HG. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol. 1999;163:4207–4212.
   PubMed Web of Science ®Google Scholar
• Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol. 2000;61:721–728.
   PubMed Web of Science ®Google Scholar
• Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003;110:163–169.
   PubMed Web of Science ®Google Scholar
• Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21–33. doi:10.1016/j.virusres.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Lee HR, Brulois K, Wong L, Jung JU. Modulation of immune system by kaposi’s sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front Microbiol. 2012;3:44. doi:10.3389/fmicb.2012.00044.
   PubMed Web of Science ®Google Scholar
• Taylor JL, Bennett HN, Snyder BA, Moore PS, Chang Y. Transcriptional analysis of latent and inducible kaposi’s sarcoma-associated herpesvirus transcripts in the K4 to K7 region. J Virol. 2005;79:15099–15106. doi:10.1128/JVI.79.24.15099-15106.2005.
   PubMed Web of Science ®Google Scholar
• Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, Johnson RP, Cohen GB, Jung JU. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi’s sarcoma-associated herpesvirus K5 protein. Immunity. 2000;13:365–374.
   PubMed Web of Science ®Google Scholar
• Johnson JM, Nicot C, Fullen J, Ciminale V, Casareto L, Mulloy JC, Jacobson S, Franchini G. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J Virol. 2001;75:6086–6094. doi:10.1128/JVI.75.13.6086-6094.2001.
   PubMed Web of Science ®Google Scholar
• Fukumoto R, Andresen V, Bialuk I, Cecchinato V, Walser JC, Valeri VW, Nauroth JM, Gessain A, Nicot C, Franchini G. In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. Blood. 2009;113:3726–3734. doi:10.1182/blood-2008-04-146928.
   PubMed Web of Science ®Google Scholar
• Pise-Masison CA, de Castro-Amarante MF, Enose-Akahata Y, Buchmann RC, Fenizia C, Washington Parks R, Edwards D, Fiocchi M, Alcantara LC, Bialuk I, et al. Co-dependence of HTLV-1 p12 and p8 functions in virus persistence. PLoS Pathog. 2014;10:e1004454. doi:10.1371/journal.ppat.1004454.
   PubMed Web of Science ®Google Scholar
• Banerjee P, Feuer G, Barker E. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and −2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. J Virol. 2007;81:9707–9717. doi:10.1128/JVI.00887-07.
   PubMed Web of Science ®Google Scholar
• Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, Wiertz EJHJ, Rowe M. The epstein-barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009;5:e1000255. doi:10.1371/journal.ppat.1000706.
   PubMed Web of Science ®Google Scholar
• Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M. The missing link in epstein-barr virus immune evasion: the BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II. J Virol. 2015;90:356–367. doi:10.1128/JVI.02183-15.
   PubMed Web of Science ®Google Scholar
• Deb Pal A, Banerjee S. Epstein-barr virus latent membrane protein 2A mediated activation of sonic hedgehog pathway induces HLA class Ia downregulation in gastric cancer cells. Virology. 2015;484:22–32. doi:10.1016/j.virol.2015.05.007.
   PubMed Web of Science ®Google Scholar
• Rancan C, Schirrmann L, Huls C, Zeidler R, Moosmann A. latent membrane protein lmp2a impairs recognition of ebv-infected cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906. doi:10.1371/journal.ppat.1004906.
   PubMed Web of Science ®Google Scholar
• Ashrafi GH, Haghshenas M, Marchetti B, Campo MS. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer. 2006;119:2105–2112. doi:10.1002/ijc.22089.
   PubMed Web of Science ®Google Scholar
• Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, Koba S, Thibodeau R, Nagase K, Simonson WT, et al. Downregulation of MHC-I expression is prevalent but reversible in merkel cell carcinoma. Cancer Immunol Res. 2014;2:1071–1079. doi:10.1158/2326-6066.CIR-14-0005.
   PubMed Web of Science ®Google Scholar
• Greenberg ME, Iafrate AJ, Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. Embo J. 1998;17:2777–2789. doi:10.1093/emboj/17.10.2777.
   PubMed Web of Science ®Google Scholar
• Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (New York, NY. 1985;229:563–566. doi:10.1126/science.2992081.
   PubMed Web of Science ®Google Scholar
• Popovic M, Lange-Wantzin G, Sarin PS, Mann D, Gallo RC. Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci USA. 1983;80:5402–5406.
   PubMed Web of Science ®Google Scholar
• Sugamura K, Fujii M, Kannagi M, Sakitani M, Takeuchi M, Hinuma Y. Cell surface phenotypes and expression of viral antigens of various human cell lines carrying human T-cell leukemia virus. Int J Cancer. 1984;34:221–228.
   PubMed Web of Science ®Google Scholar
• Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667–2677. doi:10.1182/blood-2009-02-206532.
   PubMed Web of Science ®Google Scholar
• Edwards D, Fenizia C, Gold H, de Castro-Amarante MF, Buchmann C, Pise-Masison CA, Franchini G. Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence. Viruses. 2011;3:861–885. doi:10.3390/v3060861.
   PubMed Web of Science ®Google Scholar
• Valeri VW, Hryniewicz A, Andresen V, Jones K, Fenizia C, Bialuk I, Chung HK, Fukumoto R, Parks RW, Ferrari MG, et al. Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits. Blood. 2010;116:3809–3817. doi:10.1182/blood-2010-05-284141.
   PubMed Web of Science ®Google Scholar
• Wang L, Yao ZQ, Moorman JP, Xu Y, Ning S. Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. PLoS ONE. 2014;9:e106788. doi:10.1371/journal.pone.0106788.
   PubMed Web of Science ®Google Scholar
• Lv DW, Zhang K, Li R. Interferon regulatory factor 8 regulates caspase-1 expression to facilitate epstein-barr virus reactivation in response to B cell receptor stimulation and chemical induction. PLoS Pathog. 2018;14:e1006868. doi:10.1371/journal.ppat.1006797.
   PubMed Web of Science ®Google Scholar
• Takada K, Ono Y. Synchronous and sequential activation of latently infected epstein-barr virus genomes. J Virol. 1989;63:445–449.
   PubMed Web of Science ®Google Scholar
• Daibata M, Humphreys RE, Takada K, Sairenji T. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the burkitt’s lymphoma cell line akata. J Immunol. 1990;144:4788–4793.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, et al. Lenalidomide, thalidomide, and pomalidomide reactivate the epstein-barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression. Clin Cancer Res. 2016;22:4901–4912. doi:10.1158/1078-0432.CCR-15-2242.
   PubMed Web of Science ®Google Scholar
• de Preval C, Mach B. The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA. Immunogenetics. 1983;17:133–140.
   PubMed Web of Science ®Google Scholar
• Seong RH, Clayberger CA, Krensky AM, Parnes JR. Rescue of Daudi cell HLA expression by transfection of the mouse beta 2-microglobulin gene. J Exp Med. 1988;167:288–299.
   PubMed Web of Science ®Google Scholar
• Teng Y, Takahashi Y, Yamada M, Kurosu T, Koyama T, Miura O, Miki T. IRF4 negatively regulates proliferation of germinal center B cell-derived burkitt’s lymphoma cell lines and induces differentiation toward plasma cells. Eur J Cell Biol. 2007;86:581–589. doi:10.1016/j.ejcb.2007.05.006.
   PubMed Web of Science ®Google Scholar
• Campo MS, Graham SV, Cortese MS, Ashrafi GH, Araibi EH, Dornan ES, Miners K, Nunes C, Man S. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology. 2010;407:137–142. doi:10.1016/j.virol.2010.07.044.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim EM, Lee EH, Ji KY, Yi J, Park M, Kim KD, Cho -Y-Y, Kang H-S. Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. Biochem Biophys Res Commun. 2011;409:792–798. doi:10.1016/j.bbrc.2011.05.090.
   PubMed Web of Science ®Google Scholar
• Kerkau T, Bacik I, Bennink JR, Yewdell JW, Hunig T, Schimpl A, Schubert U. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med. 1997;185:1295–1305.
   PubMed Web of Science ®Google Scholar
• Kasper MR, Collins KL. Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol. 2003;77:3041–3049.
   PubMed Web of Science ®Google Scholar
• Martinez V, Tateo M, Castilla MA, Melica G, Kirstetter M, Boue F. Lenalidomide in treating AIDS-related kaposi’s sarcoma. AIDS (London, England) . 2011;25:878–880. doi:10.1097/QAD.0b013e328344c145.
   PubMed Web of Science ®Google Scholar
• Steff M, Joly V, Di Lucca J, Feldman J, Burg S, Sarda-Mantel L, Peytavin G, Marinho E, Crickx B, Raymond E, et al. Clinical activity of lenalidomide in visceral human immunodeficiency virus-related kaposi sarcoma. JAMA Dermatol. 2013;149:1319–1322. doi:10.1001/jamadermatol.2013.5751.
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165–171. doi:10.1038/35093109.
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev. 2001;1:41–49. doi:10.1038/35095564.
   Google Scholar
• Ksienzyk A, Neumann B, Nandakumar R, Finsterbusch K, Grashoff M, Zawatzky R, Bernhardt G, Hauser H, Kröger A. IRF-1 expression is essential for natural killer cells to suppress metastasis. Cancer Res. 2011;71:6410–6418. doi:10.1158/0008-5472.CAN-11-1565.
   PubMed Web of Science ®Google Scholar
• Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, Emmel V, Marcenaro E, Leung CS, Antsiferova O, Landtwing V, et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic epstein-barr virus infection. Cell Rep. 2013;5:1489–1498. doi:10.1016/j.celrep.2013.11.041.
   PubMed Web of Science ®Google Scholar
• Johnson JM, Mulloy JC, Ciminale V, Fullen J, Nicot C, Franchini G. The MHC class I heavy chain is a common target of the small proteins encoded by the 3ʹ end of HTLV type 1 and HTLV type 2. AIDS Res Hum Retroviruses. 2000;16:1777–1781. doi:10.1089/08892220050193308.
   PubMed Web of Science ®Google Scholar
• Bai XT, Nicot C. Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis. Front Microbiol. 2012;3:400. doi:10.3389/fmicb.2012.00400.
   PubMed Web of Science ®Google Scholar
• Patil A, Manzano M, Gottwein E. CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018;132:577–586. doi:10.1182/blood-2018-01-828418.
   PubMed Web of Science ®Google Scholar
• Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH, Chen RS, Muller GW, Hughes CCW, Stirling DI. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res. 2005;25:604–616. doi:10.1089/jir.2005.25.604.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan R, Matta H, Tolani B, Triche T Jr., Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016;35:1797–1810. doi:10.1038/onc.2015.245.
   PubMed Web of Science ®Google Scholar
• Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015;126:779–789. doi:10.1182/blood-2015-02-628669.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018;11:8. doi:10.1186/s13045-017-0552-6.
   PubMed Web of Science ®Google Scholar
• Park J, Kwon M, Shin EC. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016;39:1577–1587. doi:10.1007/s12272-016-0850-5.
   PubMed Web of Science ®Google Scholar
• Azoury SC, Straughan DM, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015;15:452–462.
   PubMed Web of Science ®Google Scholar
• Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014;10:3111–3116. doi:10.4161/21645515.2014.983409.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–2501. doi:10.1056/NEJMc1713444.
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374:2542–2552. doi:10.1056/NEJMoa1603702.
   PubMed Web of Science ®Google Scholar
• Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful treatment of hiv-associated kaposi sarcoma with immune checkpoint blockade. Cancer Immunol Res. 2018;6:1129–1135. doi:10.1158/2326-6066.CIR-18-0121.
   PubMed Web of Science ®Google Scholar
• Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, et al. Multicenter phase ii study of lenalidomide in relapsed or recurrent adult T-Cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086–4093. doi:10.1200/JCO.2016.67.7732.
   PubMed Web of Science ®Google Scholar
• Popovic M, Sarin PS, Robert-Gurroff M, Kalyanaraman VS, Mann D, Minowada J, Gallo R. Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science (New York, NY. 1983;219:856–859. doi:10.1126/science.6600519.
   PubMed Web of Science ®Google Scholar
• Hamamoto Y, Takamatsu K, Kobayashi S, Yamaguchi K, Yamamoto N, Kobayashi N. Characterization of human T-cell lines harboring defective human immunodeficiency virus type 1. Virus Genes. 1989;3:141–152.
   PubMedGoogle Scholar
• Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore PS, Becker JC. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010;84:7064–7072. doi:10.1128/JVI.02400-09.
   PubMed Web of Science ®Google Scholar
• Leonard JH, Dash P, Holland P, Kearsley JH, Bell JR. Characterisation of four merkel cell carcinoma adherent cell lines. Int J Cancer. 1995;60:100–107.
   PubMed Web of Science ®Google Scholar
• Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M. TCGF (IL 2)-receptor inducing factor(s). I. regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 1985;134:1623–1630.
   PubMed Web of Science ®Google Scholar
• Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, Zielinski C, Lutter D, Hoser J, Hastreiter M, et al. Epstein-barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065–2080. doi:10.1084/jem.20160248.
   PubMed Web of Science ®Google Scholar
• Steinbruck L, Gustems M, Medele S, Schulz TF, Lutter D, Hammerschmidt W. K1 and K15 of kaposi’s sarcoma-associated herpesvirus are partial functional homologues of latent membrane protein 2A of epstein-barr virus. J Virol. 2015;89:7248–7261. doi:10.1128/JVI.00839-15.
   PubMed Web of Science ®Google Scholar
• Hoppner M, Luhm J, Schlenke P, Koritke P, Frohn C. A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells. J Immunol Methods. 2002;267:157–163.
   PubMed Web of Science ®Google Scholar